23 Jul 2020 (Nasdaq: MYOK) today announced that the U.S. Food and Drug Administration ( FDA) has granted Breakthrough Therapy Designation to

2020-06-05

MyoKardia’s Board of Directors unanimously recommends that MyoKardia shareholders tender their shares in the tender offer. The transaction is subject to customary closing conditions, including the tender of a majority of the outstanding shares of MyoKardia’s common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Learn more about Bristol Myers Squibb and our mission to discover, develop and deliver innovative medicines to patients with serious diseases. Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 billion. With the completion of the acquisition, MyoKardia shares have ceased trading on the NASDAQ Global Select Market and MyoKardia is now a wholly-owned subsidiary of Bristol Myers Squibb. Shares of MyoKardia, which have nearly doubled in value this year, surged another 57.8% to $220.31, just shy of the offer of $225 per share. The deal will also help Bristol Myers reduce some of its dependence on cancer drugs and give it access to Myokardia's lead heart drug candidate with blockbuster potential, mavacamten, adding to its existing portfolio of heart drugs that includes blood thinner Eliquis.

Myokardia drug

The transaction is subject to customary closing conditions, including the tender of a majority of the outstanding shares of MyoKardia’s common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. MyoKardia recently announced a new clinical trial of its drug, mavacamten (formerly known as MYK-461) which will compare the clinical results of mavacamten with septal reduction therapies currently used in clinical practice, i.e. the open heart surgical procedure known as septal myectomy and the catheter based procedure known as alcohol septal ablation. Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 billion.

Through the transaction, Bristol Myers Squibb gains mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy (“HCM”), a chronic heart disease with high morbidity and patient impact. A New Drug Application (“NDA”) for mavacamten for the treatment of symptomatic obstructive HCM – based on data from the EXPLORER-HCM study – is expected to be submitted to the U.S. Food and Drug Administration (“FDA”) in the first

The move was said to not be related to any problems with the company’s clinical data, but rather MyoKardia hesitated at the idea of expanding the Sanofi deal. 2020-10-05 · U.S. drugmaker Bristol Myers Squibb Co said on Monday it would buy MyoKardia Inc for about $13 billion to expand its heart drugs business and reduce its dependence on cancer treatments.

9 Dec 2020 Beta blockers; Calcium channel blockers; Digoxin; Diuretics. Anticoagulants (also called blood thinners). These medicines help to prevent

Shares of MyoKardia, which have nearly doubled in value this year, surged another 57.8% to $220.31, just shy of the offer of $225 per share. The deal will also help Bristol Myers reduce some of its dependence on cancer drugs and give it access to Myokardia's lead heart drug candidate with blockbuster potential, mavacamten, adding to its existing portfolio of heart drugs that includes blood thinner Eliquis. 2020-10-05 MyoKardia’s heart drug mavacamten is a key part of this deal. Background Of These Two Healthcare Firms. Bristol Myers Squibb is a titan in the pharmaceutical market, with revenue of over twenty-six billion dollars.

Cytokinetics Inc., a company Bristol-Myers Squibb said it would buy MyoKardia for about $13 billion to bolster its portfolio of heart disease treatments. Bristol-Myers is seeking to reduce some of its dependence on cancer Danicamtiv is MyoKardia’s most advanced clinical candidate being developed for the treatment of genetic dilated cardiomyopathy (DCM) and other targeted populations with conditions of reduced systolic function.
Iva ratio

The company 2020-10-05 · The MyoKardia drug is a small molecule designed to block the way that myosin and another protein, actin, interact in the process of muscle contraction. The drug’s effect is targeted to the heart BMS acquires MyoKardia, maker of drugs for cardiovascular disease, for $13.1B The companies expect the deal to close in the fourth quarter. MyoKardia's lead drug candidate is mavacamten, which it MyoKardia’s lead pipeline drug, code-named mavacamten, treats a chronic heart condition that can cause irregular heart rhythms in some patients and even death. Bristol plans to ask U.S. health MyoKardia will regain full rights to its drug programmes when the deal ends in April, including the experimental drugs mavacamten and MYK-491. The move was said to not be related to any problems with the company’s clinical data, but rather MyoKardia hesitated at the idea of expanding the Sanofi deal.

Danicamtiv is MyoKardia’s most advanced clinical candidate being developed for the treatment of genetic dilated cardiomyopathy (DCM) and other targeted populations with conditions of reduced systolic function. DCM is a disease of the myocardium characterized by left ventricular enlargement. 2020-05-11 MyoKardia plans to submit a New Drug Application (NDA) for U.S. regulatory approval in this indication in the first quarter of 2021. Based on mavacamten’s mechanism of action and evidence of therapeutic activity, MyoKardia plans to study mavacamten for the treatment of symptomatic non-obstructive HCM and among a targeted population of patients with heart failure with preserved ejection With MyoKardia planning to file for FDA approval of mavacamten in the first quarter of 2021, there is potential for the drug to start generating sales fairly soon.
Tsi railway

vad är kväveoxid
joyvoice uppsala
vårdcentral fjällbacka
ebay tull och moms
spotify pr agency
så mycket tjänar dom i din kommun
nar byter man dack

Bristol Myers is set to acquire heart-drug maker MyoKardia for $13.1 billion dollars. Yahoo Finance's Anjalee Khemlani shares the details.

Bristol-Myers said it expects to explore the use of mavacamten for A phase 3 pivotal trial of MyoKardia's mavacamten has demonstrated that the first-in-class drug can perform as a disease-specific therapy for hypertrophic cardiomyopathy, or HCM, by preventing the 2020-10-05 · Bristol Myers Squibb on Monday said it will pay $13.1 billion to acquire MyoKardia, a developer of medicines for genetic forms of heart disease. Bristol Myers is paying $225 per share for MyoKardia, a roughly 61% premium to the biotech's $139.60 closing price on Friday. 2020-08-30 · The results of MyoKardia’s Stage 3 EXPLORER study for its experimental drug mavacamten were presented on Saturday at the European Society of Cardiology’s virtual annual meeting and contemporaneously published in The Lancet. 2020-10-05 · “The lead asset for MyoKardia is mavacamten,” which is a “potentially revolutionary medicine for the treatment of the very serious disease of obstructive HCM.” Obstructive HCM, or hypertrophic 2020-05-11 · A n experimental drug to treat an inherited, progressive heart disease clearly improved the symptoms of patients, its maker, MyoKardia, said Monday. The full data have not yet been published or MyoKardia expects to submit marketing application to the U.S. health regulator for obstructive HCM in the first quarter of 2021 after the drug met the main goal of a late-stage study. The company 2020-10-05 · The MyoKardia drug is a small molecule designed to block the way that myosin and another protein, actin, interact in the process of muscle contraction. The drug’s effect is targeted to the heart BMS acquires MyoKardia, maker of drugs for cardiovascular disease, for $13.1B The companies expect the deal to close in the fourth quarter.